Novanta earnings beat by $0.11, revenue topped estimates

Novanta (NOVT) shares fell 14.7% after Q3 2026 earnings call, with GAAP operating margin dropping to 4.6% from 11.5% YoY. Adjusted EPS guidance for Q4 was reduced to $0.91–$0.96, below consensus of $1.02. Insider selling and macroeconomic concerns added to the decline, with shares hitting an intraday low of $120.24.

Novanta reported Q3 2026 sales of $305M, beating estimates by 1.3%. Adjusted EPS was $1.05, an 8.6% beat. Adjusted EBITDA was $80.34M, a 4.4% beat. Q4 revenue guidance is $309M, in line with estimates. Full-year adjusted EPS guidance was lowered to $3.69. Operating margin declined to 4.6% from 11.5% YoY, while free cash flow margin increased to 10% from 1.7%.

Novanta reported 3Q 2026 revenue of $305.01M, up 23.1% YoY, but net income fell 81.1% to $2.02M due to higher costs. Automation segment revenue rose 16%, while Medical Solutions grew 30.3%, including $32.9M from Riverpoint Medical acquisition. Gross margins varied across segments.

Novanta Inc. (NOVT) reported Q3 net income of $2M, or 5 cents per share, with adjusted earnings of $1.05 per share. Revenue was $305M. For Q4, it forecasts earnings of 91-96 cents per share and revenue of $306M-$312M. Full-year earnings are expected to be $3.66-$3.71 per share, with revenue of $1.14B.

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial Results for the Third Quarter 2026 • Third Quarter 2026 GAAP Revenue increased 23% to $305 million • Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted EBITDA increased 38% to $80 million

Novanta Inc. (NOVT) reported Q3 2026 revenue of $305M, up 23%, and adjusted EBITDA of $80M, up 38%. GAAP net income was $2M, while adjusted diluted EPS rose 21% to $1.05. The company expects full-year revenue of $1.135B-$1.14B, up 16%, and adjusted EBITDA of $274M-$277M.